Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ATRIAL FIBRILLATION: CURRENT PROBLEMS AND PROSPECTS OF MEDICAL CARE, TREATMENT AND PREVENTION

https://doi.org/10.20996/1819-6446-2016-12-2-196-203

Full Text:

Abstract

Modern approaches to antiarrhythmic anti-relapse therapy of atrial fibrillation are considered. Advantages and disadvantages of the main therapeutic strategies are discussed from the standpoint of evidence-based medicine. The value of strategies of rhythm control, heart rate control and «upstream therapy» in the management of patients with atrial fibrillation is specified. Results of clinical studies on the efficacy and safety of anti-arrhythmic drugs, the search for such new drugs are presented. The authors state, that possibilities of modern drug therapy are limited, development and efficiency of other methods of anti-relapse therapy are low, new groups of drugs are not effective enough or are far from clinical applications. At that the adherence to treatment of patients with atrial fibrillation is unstudied, and its influence on the treatment outcomes, prevention of complications and long-term prognosis are ignored. Authors concluded that in conditions of limited capacity for drug therapy, evaluation of the effect of adherence to treatment in patients with atrial fibrillation, and elaboration on this basis the principles and tools of therapy, taking into account social and personal characteristics, are the most perspective directions of modern arrhythmology.

About the Authors

Ju. P. Skirdenko
Omsk State Medical University, Omsk
Russian Federation


A. V. Shustov
Omsk Region Cardiology Clinic, Omsk
Russian Federation


V. V. Zherebilov
Omsk State Medical University, Omsk
Russian Federation


N. A. Nikolaev
Omsk State Medical University, Omsk
Russian Federation


References

1. Golukhova E.Z., Bulaeva N.I. Atrial fibrillation 2014: updated recommendations AHA/ACC/HRS. Kreativnaya Kardiologiya 2014; 4: 5-13. In Russian (Голухова Е.З.; Булаева Н.И. Фибрилляция предсердий 2014: по материалам обновленных рекомендаций AHA/ACC/HRS. Креативная Кардиология 2014; 4: 5-13).

2. Zinchenko Yu.V., Frolov А.I. Prophylactic antiarrhythmic therapy in patients with atrial fibrillation. Ukrainskiy Kardiologicheskiy Zhurnal 2015; 14. In Russian (Зинченко Ю.В.; Фролов А.И. Профилактическая антиаритмическая терапия у больных с фибрилляцией предсердий. Украинский Кардиологический Журнал 2015; 14).

3. Guidelines for the management of atrial fibrillation. European Heart Journal 2010; 31; 2369-429.

4. Gurevich M. А. Drug therapy of paroxysmal atrial fibrillation. Doktor.ru. Kardiologiya 2009; 3. Russian (Гуревич М. А. Лекарственная терапия пароксизмальной формы фибрилляции предсердий. Доктор.ру. Кардиология 2009; 3).

5. Hart R. G., Halperin J. L. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001; 32 (3): 803-8.

6. Kerr C.R., Humphries K.H., Talajic M., et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal AF: results from the Canadian Registry of AF. Am Heart J 2005; 149: 489-96.

7. De Vos C.B., Pisters R., Nieuwlaat R. et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725-31.

8. Friberg L., Hammar N., Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial fibrillation. Eur Heart J 2010; 31:967-75.

9. Bokarev I.N., Bespalova А.V. Management of patients with atrial fibrillation (AF). Klinicheskaya Meditsina 2013; 10. In Russian (Бокарев И.Н.; Беспалова А.В. Тактика ведения пациентов с фибрилляцией предсердий (мерцательной аритмией). Клиническая Медицина 2013; 10).

10. Ruo B., Capra A. M., Jensvold N.G. et al. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol 2004; 43: 429.

11. Wolf P., Abbott R., Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.

12. Diagnosis and treatment of atrial fibrillation. National guidelines, 2012. Available at: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Checked by 04.04.2016. In Russian (Сулимов В.А., Явелов И.С., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Национальные рекомендации, 2012. Доступно на: http://scardio.ru/content/Guidelines/FP_rkj_13.pdf. Проверено 04.04.2016.

13. Hohnloser S.H. Benefit-risk assessment of current antiarrhythmic drug therapy of atrial fibrillation. Clin Cardiol 2012; 35 (1): 28-32.

14. Kanorskij S.G. Modern drug therapy of atrial fibrillation: the choice of strategy, antiarrhythmic drugs and treatment regimens. Russkiy Meditsinskiy Zhurnal 2012; 20. Russian (Канорский С.Г. Современная медикаментозная терапия фибрилляции предсердий: выбор стратегии, антиаритмических препаратов и схем лечения. Русский Медицинский Журнал 2012; 20).

15. Hagens V.E., Ranchor A.V., Van Sonderen E. et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol 2004; 43: 241-7.

16. Camm A.J., Kirchhof P., Lip G.Y. et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-429.

17. Chung M.K., Shemanski L., Sherman D.G. et al. Functional status in rateversus rhythm-control strategies for atrial fibrillation: results of the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) functional status substudy. J Am Coll Cardiol 2005; 46: 1891-9.

18. Camm A.J., Capucci A., Hohnloser S.H. et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation J Am Coll Cardiol 2011; 57: 313-21.

19. Chen S., Yin Y., Krucoff M.W. Should rhythm control be preferred in younger atrial fibrillation patients? J Interv Card Electrophysiol 2012;35(1):71-80.

20. Caldeira D., David C., Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. Arch Cardiovasc Dis 2012; 105: 226-38.

21. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline. A Report of the American College of Cardiology Foundation. American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-23.

22. De Vos C.B. , Breithardt G., Camm A.J. et al. Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. Am Heart J 2012: 163: 887-93.

23. Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-77.

24. Hagens V., Van Veldhuisen D., Kamp O. et al. Effect of rate and rhythm control on left ventricular function and cardiac dimensions in patients with persistent atrial fibrillation: results from the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) study. Heart Rhythm 2005; 2: 19-24.

25. Opolski G., Torbicki A., Kosior D. et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126: 476-86.

26. Sullivan S.D., Orme M.E., Morais E., Mitchell S.A. Interventions for the treatment of atrial fibrillation: A systematic literature review and meta-analysis. Int J Cardiol 2013;165(2):229-36.

27. Lafuente-Lafuente C., Mouly S., Longґas-Tejero M. et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166: 719-28.

28. Miller O.N., Tarasov А.V., Pozdnyakov Yu.M., et al. The effectiveness and the impact of antiarrhythmic therapy on diastolic function of left ventricle in patients with atrial fibrillation. Rossijskij Kardiologicheskij Zhurnal 2011; 4 (90): 32-6. In Russian (Миллер О.Н., Тарасов А.В., Поздняков Ю.М., и др. Эффективность и влияние антиаритмической терапии на диастолическую функцию левого желудочка у пациентов с фибрилляцией предсердий. Российский Кардиологический Журнал 2011; 4 (90): 32-6).

29. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2011;13(7):1058.

30. Sychev O.S., SHabil'yanova L.А., Lizogub S.V., et al. The effectiveness of antiarrhythmic therapy in patients with paroxysmal and persistent forms of atrial fibrillation depending on the type of paroxysms. Ukrainskij Kardiologicheskij Zhurnal 2013; 2: 14-6. In Russian (Сычев О.С., Шабильянова Л.А., Лизогуб С.В., и др. Эффективность антиаритмической терапии у больных с пароксизмальной и персистирующей формами фибрилляции предсердий в зависимости от типа пароксизмов. Украинский Кардиологический Журнал 2013; 2: 14-6).

31. Babaev F., Volkov V., KHezheva F. Therapy of patients with arterial hypertension and paroxysmal form of atrial fibrillation. Vrach 2013; 3: 23-5. In Russian (Бабаев Ф.; Волков В.; Хежева Ф. Терапия пациентов с артериальной гипертензией и пароксизмальной формой фибрилляции предсердий. Врач 2013; 3: 23-5).

32. Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Philadelfia: Saunders; 2011.

33. Pozdnyakov Yu.M., Tarasov А.V. Violations of rhythm and conductivity of heart. Part I. Moscow: VINITI; 2005. In Russian (Поздняков Ю.М., Тарасов А.В. Нарушения ритма и проводимости сердца. Ч. I. М.: ВИНИТИ; 2005).

34. Schwartz P.J., Priori S.G., Napolitano C. Long QT syndrome. Cardiac Electrophysiology: From Cell to Bedside. 3rd ed. Zipes DP, Jalefe J eds. Philadelphia: WB Saunders; 2000: 615-40.

35. Lafuente-Lafuente C., Longas-Tejero M.A., Bergmann J.F., Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2015;3:CD005049.

36. Kirchhof P., Andresen D., Bosch R. et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, openlabel, blinded endpoint assessment trial. Lancet 2012; 380: 238-46.

37. Fomina I.G., Tarzimanova А.I., Vetluzhskij А.V., Аbramova А.А. Propafenone in restoring sinus rhythm in patients with persistent form of atrial fibrillation. "PROMETEI" is an open, multicenter, pilot study in the Russian Federation (part II). Kardiovaskuljarnaja Terapija i Profilaktika 2005; 4(5): 65-8. In Russian (Фомина И.Г., Тарзиманова А.И., Ветлужский А.В., Абрамова А.А. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» открытое, мультицентровое, пилотное исследование в Российской Федерации (часть II). Кардиоваскулярная Терапия и Профилактика 2005; 4(5): 65-8).

38. Nieuwlaat R., Hohnloser S.H., Connolly S.J. Effects of dronedarone in patients with permanent atrial fibrillation during the ATHENA study [abstract]. Eur Heart J 2011; 32: 618.

39. Singh B.N., Connolly S.J., Crijns H.J.G.M. et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. New Engl J Med 2007; 357: 987-99.

40. Le Heuzey J.Y., De Ferrari G.M., Radzik D., et al. A short-term, randomized, double-blind, parallelgroup study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597-605.

41. Lehner J.P., Connolly S. Sanofi provides MultaqR Phase IIIb PALLAS trial update. Available at: http://www.europeanpharmaceuticalreview.com/8099/news/industry-news/sanofi-providesmultaq®-phase-iiib-pallas-trial-update. Checked by: 25.02.2016.

42. Piccini J.P., Hasselblad V., Peterson E.D. et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54(12): 1089-95.

43. Connolly S., Camm A., Halperin J. et al. Dronedarone in High-Risk Permanent Atrial Fibrillation. N Engl J Med 2011; 365 (24): 2268-76.

44. Camm A.J., Kirchhof P., Lip G.Y., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010; 12: 1360-420.

45. FDA Drug Safety Communication: Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events, 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/ ucm264059.htm. Checked by 11.04.2016.

46. Kober L., Torp-Pedersen C., McMurray J.J. et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358: 2678-87.

47. Gillis A.M., Verma A., Talajic M. et al. Canadian cardiovascular society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol 2011; 27: 47-59.

48. Le Heuzey J.Y., De Ferrari G.M., Radzik D. et al. A short-term, randomized, double-blind, parallel group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the dionysos study. J Cardiovasc Electrophysiol 2010; 21: 597-605.

49. Burashnikov A., Sicouri S., Di Diego J.M. et al. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol 2010; 56: 1216-24.

50. Yuricheva Yu.А., Majkov E.B., Sokolov S.F et al. The efficacy and safety of a new anti-arrhythmic drug class III of diferitele in the relief of persistent forms of atrial fibrillation and atrial flutter. Kardiologicheskii Vestnik 2011; 6 (1): 13-8. In Russian (Юричева Ю.А., Майков Е.Б., Соколов С.Ф. и др. Эффективность и безопасность нового антиаритмического препарата III класса ниферидила в купировании персистирующей формы фибрилляции и трепетания предсердий. Кардиологический Вестник 2011; 6 (1): 13-8).

51. Savelieva I., Camm J. Antiarrhythmic drug therapy for atrial fibrillation: current antiarrhythmic drugs, investigational agent and innovative approaches. Europace 2008; 10: 647-65.

52. Bogus S.K., Gordeeva S.V., Rudomanova V.V., Ivanchura G. S. Comparative evaluation of antiarrhythmic effect of lidocaine and derivatives of indole (sbt-151, sbt-818) neurogenic atrial fibrillation. Kubanskiy Nauchnyy Meditsinskiy Vestnik 2009; 8: 12-6. In Russian (Богус С.К., Гордеева С.В., Рудоманова В.В., Иванчура Г. С. Сравнительная оценка антиаритмического влияния лидокаина и производных индола (sbt-151, sbt-818) при нейрогенной фибрилляции предсердий. Кубанский Научный Медицинский Вестник 2009; 8: 12-6).

53. Lishmanov Yu.B., Maslov L.N., Naryzhnaya N.V. et al. The endogenous opioid system as a link term and long-term adaptation of organism to extreme influences. Prospects of clinical application of opioid peptides. Vestnik RAMN 2012; 6:73-82. In Russian (Лишманов Ю.Б.; Маслов Л.Н.; Нарыжная Н.В. с соавт. Эндогенная опиатная система как звено срочной и долговременной адаптации организма к экстремальным воздействиям. Перспективы клинического применения опиатных пептидов. Вестник РАМН 2012; 6:73-82).

54. TRACE Study Group. A clinical trial of angiotensin-converting enzyme inhibitor Trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study. N Engl J Med 1995; 333: 1670—6.

55. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-9.

56. Lindholm L.H., Ibsen H., Danlof B. et al., for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-10.

57. Zhirov I.V. The place of the antagonists of receptors of angiotensin II in chronic heart failure: results of the CHARM program. Kardiologija i Angiologija 2011; 3: 11-4. In Russian (Жиров И.В. Место антагонистов рецепторов ангиотензина II в лечении хронической сердечной недостаточности: итоги программы CHARM. Кардиология и Ангиология 2011; 3: 11-4).

58. Kobalava Zh.D. Early, stable control of blood pressure is the guarantor of improved prognosis in arterial hypertension high risk: results from a mega-study VALUE. Russkij Medicinskij Zhurnal 2004; 15:

59. In Russian (Кобалава Ж.Д. Ранний, стабильный контроль АД гарант улучшения прогноза при артериальной гипертонии высокого риска: результаты мега-исследования VALUE. Русский Медицинский Журнал 2004; 15: 922).

60. Kalus J.S., Coleman C.I., White C.M. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol 2006; 46: 21-8.

61. Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am. j. cardiol. 2007; 99: 1544-1548.

62. Lip G.Y., Tse H.F., Lane D.A. Atrial fibrillation. Lancet 2012; 379: 648-61.

63. Nodari S., Triggiani M., Campia U. et al. N-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective randomized study. Circulation 2011; 124: 1100-06.

64. Bianconi L., Calt L., Mennuni M. et al. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace 2011; 13 (2): 174-81.

65. Savelieva I., Kakouros N., Kourliouros A., Camm A. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011; 13: 610-25.

66. Macchia A., Grancelli H., Varini S., Nul D. et al. Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation. Results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation). Trial J Am Coll Cardiol 2013; 61(4): 463-8.


For citation:


Skirdenko J.P., Shustov A.V., Zherebilov V.V., Nikolaev N.A. ATRIAL FIBRILLATION: CURRENT PROBLEMS AND PROSPECTS OF MEDICAL CARE, TREATMENT AND PREVENTION. Rational Pharmacotherapy in Cardiology. 2016;12(2):196-203. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-2-196-203

Views: 455


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)